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ABSTRACT
Objective: The current study assessed the criterion validity of the Montreal Cognitive Assessment (MoCA)
as a short cognitive screen for use in addiction health care. Method: Eighty-two patients were assessed
with two parallel versions of the MoCA; at intake (baseline) and directly preceding an extensive
neuropsychological assessment (NPA) approximately 8 weeks later (follow-up). Results: Of all included
patients, 54.9% were classified as having substance-induced neurocognitive disorder. The most common
primary substance of abuse was alcohol (70.7%). The criterion validity was determined predictively and
concurrently, and sensitivities of .56 and .67 and specificities of .62 and .73 were found, respectively.
Conclusion: While the MoCA is an adequate screen when administered at the same time as the NPA, the
predictive validity of administering this cognitive screen at intake is limited. Furthermore, the relation
between MoCA domain scores and the performance on their corresponding cognitive domain in the
NPA is more reliable when the MoCA is administered at the same time as the NPA. While the MoCA can
be used to screen for cognitive impairments in patients in addiction health care, the instrument’s
sensitivity is not optimal, which should be taken into account when interpreting results.
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Introduction
About 0.6% of the adult population worldwide (an estimated
29.5 million) suffer from substance use disorder (SUD; United
Nations Office on Drugs and Crime, 2017). SUD affects the
individual in social, physical and economical ways (Laudet,
Savage, & Mahmood, 2002) and may result in cognitive
impairments interfering with treatment (Aharonovich et al.,
2006; Bates, Pawlak, Tonigan, & Buckman, 2006; Copersino
et al., 2012). The Diagnostic and Statistical Manual of Mental
Disorders (5th ed.; DSM-5; American Psychiatric Association,
2013) introduced the term “neurocognitive disorder” (NCD)
in which the subtype substance-induced NCD can be classi-
fied as either major or mild, based on severity and everyday
limitations. Cognitive impairments in patients with SUD have
an estimated prevalence of 30–80% (Copersino et al., 2009).
The exact prevalence of substance-induced NCD is, however,
difficult to establish based on the existing literature (Toledo-
Fernández et al., 2017).
The effects of chronic substance use on cognitive function-
ing are both acute and chronic and vary across substances,
resulting in decreased treatment adherence, lower self-efficacy
and less treatment retention (Aharonovich et al., 2006; Bates
et al., 2006; Copersino et al., 2012). Therefore, insight into an
individual’s cognitive functioning is crucial, as it enables to
personalize and optimize treatment effectiveness (Allen,
Goldstein, & Seaton, 1997; Bates, Buckman, & Nguyen,
2013; Sofuoglu, Sugarman, & Carroll, 2010). Often patients
with SUD lack insight into their NCD, as indicated by a lack
of correlation between objectively measured and subjectively
experienced cognitive deficits (Horner, Harvey, & Denier,
1999; Walvoort, van der Heijden, Kessels, & Egger, 2016).
Although neurocognitive assessment can accurately detect
the pattern and severity of cognitive impairment in patients
with SUD, the administration of such an extensive neuropsy-
chological assessment (NPA) is not always feasible. Therefore,
this study investigated the validity of a short and easy-to-
administer cognitive screen, the Montreal Cognitive
Assessment (MoCA; Nasreddine et al., 2005), in patients
with SUD.
Originally developed to detect mild cognitive impairment
(MCI; Nasreddine et al., 2005), the MoCA has also been
found to be valid in SUD for detecting cognitive deficits
(Copersino et al., 2009; Ridley et al., 2018; Rojo-Mota,
Pedrero-Pérez, Ruiz-Sánchez de León, Llanero-Luque, &
Puerta-García, 2013). However, only one study in patients
with alcohol use disorders (AUD) has correlated the MoCA
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to the gold standard NPA performance (Ewert et al., 2018),
with no studies in users of other substances.
The current prospective study assessed the criterion valid-
ity of the MoCA as a screen for cognitive impairment in a
sample of patients with SUD. First, the optimal cutoff for use
in addiction health care was established. Next, the criterion
validity was assessed by comparing MoCA results with an
extensive NPA. Additionally, the interaction of substance
type, abstinence duration and MoCA performance has been
examined. In order to maximize the external validity of the
design, this study was designed to comply as much as possible
with treatment as usual in all participating institutions.
Method
Design
A prospective study was performed with two time points of
assessment using two authorized and validated parallel ver-
sions of the MoCA (Costa et al., 2012). MoCA version 7.1 was
administered at intake (baseline) and MoCA version 7.2
directly preceding the NPA at follow-up approximately
8 weeks later. Data were collected between August 2012 and
March 2015. The study was approved by the internal review
boards of all participating health-care centers and the research
board of the Nijmegen Institute for Scientist-Practitioners in
Addiction.
Participants
The aim was to recruit a total of 100 outpatients seeking
treatment for SUD from four participating addiction health-
care centers in the Netherlands (IrisZorg, Novadic-Kentron,
Tactus and Vincent van Gogh for Mental Health). This study
is part of a larger study (N = 691), for which the inclusion
criteria were (1) dependency or abuse of a substance (exclud-
ing nicotine) or behavior; (2) age 18–75; and (3) signed
informed consent for participation at baseline and/or follow-
up. The exclusion criterion was an inability to administer the
MoCA, due to for instance: a neurological (e.g., stroke,
dementia, traumatic brain injury) or very unstable acute psy-
chiatric disorder, severe lack of motivation, or insufficient
Dutch language skills. Patients were included regardless of
abstinence to increase the external validity of the design.
Materials
Montreal Cognitive Assessment
The MoCA (Nasreddine et al., 2005) consists of twelve ele-
ments measuring seven cognitive domains. These domains
include executive functioning; visuospatial abilities; attention,
concentration and working memory (called “attention” from
now on); language; abstract reasoning; memory; and orienta-
tion. A total score is calculated, with a maximum of 30 points.
Nasreddine et al. (2005) found a score of ≤25 to be indicative
of MCI. However, several studies have identified different
cutoff scores for different populations (Julayanont, Phillips,
Chertkow, & Nasreddine, 2013). The validity of the MoCA,
including both alternate forms, has been established in
detecting MCI, with sensitivities and specificities ranging
from .90 to 1.00 and .57 to .62, respectively. Alternate-form
reliability for healthy controls ranged from .52 to .69 and all
versions were found to be equivalent in previous research
(Costa et al., 2012; Nasreddine & Patel, 2016). The authorized
Dutch translations of two parallel versions were used (see
www.mocatest.org for materials and instructions).
Neuropsychological assessment
The tests included in the NPA, that was administered at
follow-up, were selected based on the cognitive domains tar-
geted by the MoCA, thus assessing a broad range of cognitive
functions. The allocation of the NPA (sub)tests and MoCA
elements to each cognitive domain was based on DSM-5
criteria for NCD (pp. 593–595; American Psychiatric
Association, 2013) and is summarized in Appendix 1.
Measurements in the addictions for triage and evaluation
(MATE 2.1)
The MATE 2.1 (Schippers, Broekman, & Buchholz, 2011) is
part of the intake procedure and consists of an interview and
self-report questionnaires for collecting relevant patient char-
acteristics. In this study, Section 1 ‘Substance use’ and Section
3 ‘History of treatment for substance use disorders’ were used.
Procedure
At baseline, the MATE 2.1 was administered and written
informed consent was obtained. MoCA version 7.1 was admi-
nistered by trained professionals during intake procedure. For
administration of the NPA (follow-up) an appointment
approximately 6–8 weeks later was made. The NPA procedure
was fixed for all institutions and administration was done by
trained psychologists. All professionals were trained in MoCA
and/or NPA administration in accordance with the test man-
uals, by the coordinator of this study.
Recruitment for follow-up was based on random selection
(i.e., one in eight patients of the large study were randomly
selected for a follow-up), indication (i.e., based on care as
usual), or both. Three patients with a behavioral disorder
without substance use were excluded for this study. At fol-
low-up, MoCA version 7.2 was administered preceding the
NPA. Prior to both baseline and follow-up, a self-reported
estimation of substance use in the week before administration,
or abstinence duration (if >7 days) was obtained.
Analyses
Patient characteristics
For determining the presence of NCD, criteria for sub-
stance-induced NCD of the DSM-5 (American Psychiatric
Association, 2013) were combined with the “cognitive
impairment, no dementia” criteria as outlined in van den
Berg, Kessels, de Haan, Kappelle, and Biessels (2005). All
raw scores of the NPA were transformed into standard
z-scores, according to the normative data. These standard
z-scores were classified as: 0 = average (≥–1.00); −1 = below
average (between −1.00 and −1.65); −2 = impaired (≤–1.65).
An average score for a domain of ≤–1.00 was considered to
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be impaired. If at least two out of all seven NPA domains
were impaired, the patient was classified as having sub-
stance-induced NCD. Nine patients had missing data in
one or more NPA domain, but the remaining results were
sufficient to validly classify each patient. Mean NPA domain
scores and patient characteristics were compared between
patients with and without NCD by using independent
t-tests, chi-square tests or Mann–Whitney U tests (non-
normal variables).
Criterion validity
Level of education was classified on a seven-point scale ranging
from 1 = less than primary school to 7 = university degree or
higher (Duits & Kessels, 2014), a classification system compar-
able to the International Standard Classification of Education
(United Nations Educational Scientific and Cultural
Organization, 2012). As it was found that years of education
affects performance on the MoCA (Chertkow, Nasreddine,
Johns, Phillips, & McHenry, 2011; Nasreddine et al., 2005),
Spearman’s rho correlations were used to relate the unadjusted
MoCA total scores at baseline and follow-up to this level of
education. Based on the studies by Chertkow et al. (2011) and
van der Elst, van Boxtel, van Breukelen, and Jolles (2005), the
MoCA total score was then adjusted for education (low level of
education, classifications 1–3: two additional points; average
level of education, classifications 4 and 5: one additional point;
and highly educated patients, classifications 6 and 7: no addi-
tional points), with the maximum MoCA total score remaining
30 in all cases. MoCA results were then explored and differences
between patients with and without NCD were computed using
independent t-tests. Furthermore, MoCA domain scores were
correlated with mean z-scores on the corresponding NPA
domain, and systematic differences between MoCA domain
and total scores at baseline and at follow-up were assessed
with paired t-tests.
The predictive validity was assessed by computing a recei-
ver operating characteristic curve with the corresponding area
under the curve (AUC) for the MoCA total score at baseline,
with NPA classification (NCD or no-NCD) at follow-up as a
criterion. The cutoff point was determined by the optimal
sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV). After applying the cutoff to
the data, overall agreement and chance-adjusted agreement
(Cohen’s kappa) were determined. The concurrent validity
was assessed in the same way as the predictive validity by
using MoCA and NPA results at follow-up.
Substance type and abstinence duration
The influence of substance type and abstinence duration on
MoCA performance at follow-up was estimated using logistic
regression with abstinence duration, substance type (alcohol
versus other drugs), MoCA total score, and interactions between
each as predictors, with NCD classification (NCD versus no-
NCD) as the dependent variable. The Outlier Labelling Rule
(Hoaglin & Iglewicz, 1987) was used to exclude outliers, leading
to the exclusion of one outlier for abstinence duration. All data
were computed and analyzed with IBM SPSS version 24.0.
Results
Patient characteristics
A total of 82 patients were included in this study, 54.9% of
whom were classified as having NCD based on the NPA
results. Mean NPA-domain scores differed significantly
between patients with and without NCD for all cognitive
domains except orientation (Table 1).
The overall mean age was 44.1 (SD = 13.77) and 68.3% were
men. The most prevalent primary problem substance of abuse
was alcohol (70.7%). More patients were abstinent at follow-up
than at baseline (an increase of 28.0%). The majority (42.7%)
was not abstinent at either time point. Except for age and
marital status, both patient groups were comparable (Table 2).
Criterion validity
Montreal Cognitive Assessment
Level of education correlated with the unadjusted MoCA total
scores both at baseline (ρ = .421, p < .001) and at follow-up
(ρ = .550, p < .001).
Patients with NCD performed significantly worse on the
MoCA than patients without NCD, both at baseline and at
follow-up. The same was true for the MoCA domain executive
functioning. At baseline, the difference in performance on the
MoCA domain memory was also significant, while perfor-
mance on the MoCA domains language and abstract reason-
ing differed significantly between both patient groups at
follow-up. Performance on the other MoCA domains did
not differ significantly between both patient groups (Table 3).
At baseline, correlations between performance on the MoCA
and NPA were significant for the domains executive functioning
(r = .238, p = .032), abstract reasoning (r = .300, p = .006), and
memory (r = .423, p < .001). At follow-up, there was an almost
perfect correspondence between MoCA and NPA performance:
all MoCA domain scores were significantly correlated to the
corresponding NPA domain (executive functioning: r = .328,
p = .003; visuospatial abilities: r = .241, p = .029; attention:
r = .396, p < .001; abstract reasoning: r = .542, p < .001; memory:
r = .455, p < .001; orientation: r = .229, p = .043).
Predictive validity at baseline
An AUC value of .676 was found (p = .006; Figure 1) and a
cutoff score of 24 yielded the most optimal sensitivity (.56),
specificity (.62), PPV (64.1%), and NPV (53.5%), using the
NPA as gold standard. Applying this cutoff score, 39 out of
Table 1. Mean (SD) performance in z-scores for each domain of the neurop-
sychological assessment (NPA) for patients with and without neurocognitive
disorders (NCD) and in the total sample.
NPA domain
Total
(n = 82)
NCD
(n = 45)
No-NCD
(n = 37) p-Value
Executive functioning −0.10 (0.89) −0.32 (1.02) 0.16 (0.62) .011*
Visuospatial abilities −0.83 (0.99) −1.21 (0.88) −0.37 (0.92) <.001***
Attention −0.78 (0.90) −1.16 (0.71) −0.32 (0.89) <.001***
Abstract reasoning −0.71 (0.83) −1.00 (0.85) −0.35 (0.64) <.001***
Memory −0.67 (1.01) −1.00 (1.02) −0.27 (0.86) .001**
Orientation 4.20 (1.11) 4.05 (1.32) 4.36 (0.80) .211
Processing speed −0.61 (0.89) −1.03 (0.80) −0.10 (0.71) <.001***
*p < .05; **p < .01; ***p < .001.
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82 patients were classified as having NCD, while 45 out of 82
patients were classified as having NCD based on the NPA. The
overall agreement with the NPA was 58.5% and the chance-
adjusted agreement was 17.5% (Table 4).
Concurrent validity at follow-up
An AUC of .745 was found (p < .001; Figure 1) and a cutoff
score of 25 yielded the most optimal sensitivity (.67), specifi-
city (.73), PPV (75.0%), and NPV (64.3%), using the NPA as
Table 2. Patient characteristics for patients with and without neurocognitive disorders (NCD) and in the total sample.
Total
(n = 82)
NCD
(n = 45)
No-NCD
(n = 37) p-Value
Mean age in years (SD) 44.1 (13.8) 46.9 (13.9) 40.8 (13.0) .045*
Sex, men (%) 56 (68.3) 30 (66.7) 26 (70.3) .814a
Level of education (%) .251
Low educated
Average educated
High educated
14 (17.1)
59 (72.0)
9 (11.0)
5 (11.1)
34 (75.6)
6 (13.3)
9 (24.3)
25 (67.6)
3 (8.1)
Marital status (%) .028*
Single
With partner/married
Separated/divorced
Widowed
26 (31.7)
34 (41.5)
20 (24.4)
2 (2.4)
12 (26.7)
15 (33.3)
16 (35.6)
2 (4.4)
14 (37.8)
19 (51.4)
4 (10.8)
0 (0.0)
Inclusion based on (%) .179
Indication
Selection
Both
59 (72.0)
17 (20.7)
6 (7.3)
35 (77.8)
6 (13.3)
4 (8.9)
24 (64.9)
11 (29.7)
2 (5.4)
Primary problem substance (%) .864
Alcohol
Cannabis
Stimulants
Opiates
58 (70.7)
13 (15.9)
8 (9.8)
3 (3.7)
33 (73.3)
6 (13.3)
4 (8.9)
2 (4.4)
25 (67.6)
7 (18.9)
4 (10.8)
1 (2.7)
Abstinent, yes (%)
At baseline
Mean duration in days (SD)
At follow-up
Mean duration in days (SD)
20 (75.6)
44.9 (77.8)
43 (52.4)
62.7 (45.4)
13 (28.9)
23.5 (12.6)
26 (57.8)
62.6 (45.4)
7 (18.9)
84.4 (126.5)
17 (45.9)
62.9 (46.8)
.317a
.141b
.375a
.950b
Abstinent at (%) .604
Baseline, not follow-up
Follow-up, not baseline
Both baseline and follow-up
Neither baseline nor follow-up
4 (4.9)
27 (32.9)
16 (19.5)
35 (42.7)
2 (4.4)
15 (33.3)
11 (24.4)
17 (37.8)
2 (5.4)
12 (32.4)
5 (13.5)
18 (48.6)
Mean interval between baseline and follow-up in days (SD) 92.9 (83.6) 104.0 (101.0) 79.5 (54.04) .394b
History of treatment, yes (%) 41 (50.0) 24 (53.3) 17 (45.9) .657a
aFisher’s exact test.
bMann–Whitney U test.
*p < .05.
Table 3. Mean (SD) and t-test results for the Montreal Cognitive Assessment (MoCA) domain and total scores at baseline and follow-up, for
patients with and without neurocognitive disorders (NCD) and for the total sample.
MoCA domain
Total
(n = 82)
NCD
(n = 45)
No-NCD
(n = 37)
t(80)
(p-Value)
Executive functioning B
F
t(81)
1.02 (0.70)
1.38 (0.60)
–4.89 (< .001***)
0.82 (0.65)
1.22 (0.60)
1.27 (0.69)
1.57 (0.56)
3.02 (.003*)
2.69 (.009*)
Visuospatial abilities B
F
t(81)
2.49 (0.93)
2.99 (0.91)
–4.33 (< .001***)
2.40 (0.96)
2.82 (0.96)
2.59 (0.90)
3.19 (0.81)
0.94 (.350)
1.85 (.069)
Attention B
F
t(81)
5.09 (1.15)
5.49 (0.79)
–3.22 (.002**)
4.89 (1.25)
5.36 (0.91)
5.32 (0.97)
5.65 (0.59)
1.73 (.087)
1.76 (.082)
Language B
F
t(81)
4.27 (0.79)
3.61 (1.04)
5.36 (< .001***)
4.27 (0.78)
3.40 (1.03)
4.27 (0.80)
3.86 (1.00)
0.02 (.984)
2.06 (.043*)
Abstract reasoning B
F
t(81)
1.30 (0.75)
1.41 (0.68)
–1.10 (.274)
1.24 (0.74)
1.24 (0.74)
1.38 (0.76)
1.62 (0.55)
0.81 (.423)
2.65 (.010*)
Memory B
F
t(81)
2.93 (1.62)
3.11 (1.60)
–1.06 (.293)
2.53 (1.65)
2.82 (1.68)
3.41 (1.46)
3.46 (1.45)
2.51 (.014*)
1.82 (.073)
Orientation B
F
t(81)
5.62 (0.68)
5.78 (0.47)
–1.89 (.063)
5.64 (0.68)
5.76 (0.53)
5.59 (0.69)
5.81 (0.40)
−0.33 (.743)
0.53 (.601)
Total score B
F
t(81)
23.78 (3.37)
24.83 (3.31)
–3.33 (.001**)
22.78 (3.64)
23.60 (3.45)
25.00 (2.57)
26.32 (2.43)
3.23 (.002*)
4.19 (< .001***)
B = baseline; F = follow-up.
*p < .05; **p < .01; ***p < .001.
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gold standard. Applying this cutoff score, 40 out of 82 patients
were classified as having NCD. The overall agreement with
the NPA was 69.5% and the chance-adjusted agreement was
39.2% (Table 4).
Systematic differences between MoCA versions 7.1 and 7.2
Paired t-tests between MoCA results for version 7.1 (baseline)
and 7.2 (follow-up) showed that only the domains abstract
reasoning, memory, and orientation did not differ signifi-
cantly. All other domains and the MoCA total score differed
significantly between both versions. For all domains except
language, mean scores on MoCA version 7.2 were higher
(Table 3).
Substance type and abstinence duration
The logistic regression model was statistically significant
(χ2(7) = 16.58, p = .020), correctly classifying 69.0% of cases.
However, neither the predictors nor any interaction between
the predictors in the model were statistically significant.
Discussion
This study is the first to examine the MoCA as a short
cognitive screen in a sample of patients with SUD, using an
extensive NPA as benchmark. The results show that admin-
istration of the MoCA at baseline resulted in a worse validity
than the MoCA administered at follow-up. Also, while at
follow-up all MoCA cognitive domains correlated with the
corresponding domain of the NPA, at baseline only the
MoCA domains executive functioning, abstract reasoning,
and memory significantly predicted NPA performance
8 weeks later.
These findings are partly in line with other MoCA studies
(Alarcon, Nalpas, Pelletier, & Perney, 2015; Oudman et al., 2014;
Wester, Westhoff, Kessels, & Egger, 2013) where only Alarcon
et al. (2015) reported a higher predictive validity. There are,
however, important differences between these studies and the
current . First, only homogeneous groups of patients with AUD
were included in previous studies, limiting their external validity.
Second, patients in those studies were abstinent for at least
Figure 1.
Table 4. Relation between the Montreal Cognitive Assessment (MoCA) total
score and neurocognitive disorders (NCD or no-NCD), at baseline and follow-
up. Statistical significance of the area under the curve (AUC) is reported.
MoCA at baseline MoCA at follow-up
AUC (SE) .676 (.059) .745 (.055)
p-Value .006* <.001**
Cutoff (≤) Sensitivity Specificity Sensitivity Specificity
20 .289 .919 .200 .973
21 .378 .892 .311 .946
22 .400 .838 .356 .865
23 .444 .811 .444 .865
24 .556# .622# .511 .838
25 .756 .459 .667# .730#
26 .911 .297 .822 .541
27 .933 .162 .889 .378
PPV (%) at # 64.1 75.0
NPV (%) at # 53.5 64.3
Accuracy (%) at # 58.5 69.5
Cohen’s kappa (%) at # 17.5 39.2
≤Optimal cutoff (n, %) 39 (47.6) 40 (48.8)
#MoCA cutoff with most optimal sensitivity and specificity; PPV = positive pre-
dictive value; NPV = negative predictive value.
*p < .01; **p < .001.
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1 week (Alarcon et al., 2015) to a minimum of 6 months
(Oudman et al., 2014), while in clinical practice patients are
often not abstinent at intake. To date, only one study in AUD
related MoCA performance directly to an NPA (Ewert et al.,
2018), which is considered to be the gold standard for the
assessment of cognitive impairments (Lezak, Howieson, Bigler,
& Tranel, 2012). Ewert et al. (2018) found a higher education-
adjusted cutoff score than was currently found to be indicative of
cognitive impairment, using a homogeneous group of hospita-
lized patients with AUD. The only study in a heterogeneous
group of patients with SUD (Copersino et al., 2009) was more
in line with the present findings – albeit that slightly better
psychometric properties were found.
Regarding the relation between MoCA domain scores at
baseline and NPA domain performance at follow-up, caution
should be taken when interpreting the MoCA domain scores.
This is in line with a previous study also showingMoCA domain
scores to be poor predictors of impairment on neuropsycholo-
gical tests (Moafmashhadi & Koski, 2013). The difference in
findings between the predictive and concurrent validity can be
explained by the interval between baseline and follow-up.
Abstinence could also be an explanation as cognitive recovery
is likely to occur with sustained abstinence in AUD (Stavro,
Pelletier, & Potvin, 2013; van Holst & Schilt, 2011), cannabis
(Lyons et al., 2004), and stimulants (Iudicello et al., 2010;
Vonmoos et al., 2014; Wood, Sage, Shuman, & Anagnostaras,
2014; Zhong et al., 2016). Althoughmore patients were abstinent
at follow-up, we did not find a significant effect of abstinence on
MoCA performance in our statistical model.
There are several strengths to the current study. First,
the heterogeneity of the sample largely represents clinical
practice, which makes the results generalizable to addiction
health care. Second, the used adjustment method for level
of education (based on Chertkow et al., 2011) is more fine-
grained than the original adjustment method by Nasreddine
et al. (2005). Third, the extensive gold standard NPA, using
widely used, valid and reliable tests, made analysis of spe-
cific domains and comparisons between patients with or
without NCD possible, which has not been done before in a
heterogeneous group of patients with SUD. Fourth, parallel
MoCA versions were administered at two time points,
which made it possible to assess validity predictively and
concurrently. Finally, the effects of substance type and
abstinence duration on MoCA performance were taken
into account.
Although a moderate concurrent validity of the MoCA
as compared to the NPA was found, it should be stressed
that using a MoCA cutoff score of 25 results in only 66.7%
of patients with NCD being classified correctly. Therefore,
we underscore the fact that the MoCA as a screen can
never substitute an extensive NPA. Therefore, a subsequent
extensive NPA is recommended, especially in patients who
perform above or at the cutoff point, given the low
sensitivity.
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Appendix 1
Cognitive domains with the corresponding elements of the Montreal Cognitive Assessment (MoCA) and (sub)tests of the neuropsychological
assessment (NPA)
Cognitive domain MoCA element (score range) NPA element (used score)
Executive functioning Alternating trail making (0–1)
Verbal fluency (0–1)
D-KEFS TMT
Letter-number switching (scaled score)
Number sequencing (scaled contrast score*)
Letter sequencing (scaled contrast score*)
Stroop CWT
Interference score (t-score)
Visuospatial abilities Figure copy (0–1)
Clock drawing (0–3)
WAIS-IV-NL
Block design (scaled score)
RCFT
Copy (t-score)
Attention Digit span (0–2)
Sustained attention (0–1)
Serial subtraction (0–3)
WAIS-IV-NL
Digit span forward (scaled score)
Digit span backward (scaled score)
Language Naming (0–3)
Sentence repetition (0–2)
-
Abstract reasoning Abstraction (0–2) WAIS-IV-NL
Similarities (scaled score)
DART (deviation IQ)
Memory Delayed recall (0–5) RAVLT
Total correct (t-score)
Delayed recall (t-score)
RCFT
Immediate reproduction (t-score)
Orientation Orientation (0–6) CST-14 (raw score)
Processing speed - Stroop CWT
Word reading (t-score)
Color naming (t-score)
D-KEFS TMT
Motor speed (scaled score)
D-KEFS TMT = Delis-Kaplan Executive Function System Trail Making Test (Delis, Kaplan, & Kramer, 2007); Stroop CWT = Stroop Color
Word Test (Hammes, 1971); WAIS-IV-NL = Wechsler Adult Intelligence Scale–IV–Dutch (Wechsler, 2012); RCFT = Rey-Osterrieth
Complex Figure Test (Meyers & Meyers, 1995); DART = Dutch Adult Reading Test (Schmand, Lindeboom, & van Harskamp, 1992);
RAVLT = Rey Auditory Verbal Learning Test (Saan & Deelman, 1986); CST-14 = Cognitive Screening Test–14 (de Graaf & Deelman,
1991); * = Scaled score obtained by contrasting performance on the number sequencing and letter sequencing conditions against
performance on the number-letter switching condition.
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